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ABSTRACT

IDIOPATHIC PULMONARY FIBROSIS:
DIAGNOSIS, MANAGEMENT, AND THE SEARCH FOR A CURE
Daniel Fioret
August 2, 2012
Idiopathic pulmonary fibrosis (IPF) is a fibrotic lung disease with poor prognosis.
To address this disease broadly, the candidate engaged in clinical work, literature
analysis, database analysis, and laboratory work. The clinical work culminated in a case
report that highlights the controversies inherent in the diagnosis and treatment of IPF.
The literature analysis discusses ongoing clinical trials and challenges inherent in the
management of IPF. Evaluation of a national database unveiled information about the
burden of IPF on the healthcare system. Finally, the laboratory work examined the role
of oxidant stress and the interaction of lung fibroblasts and lung cancer cells. Altogether,
the document defines the clinical presentation of IPF, summarizes current treatment
strategies and obstacles to the development of effective therapies, describes the burden of
IPF to healthcare regarding hospitalization rates and costs, and beings to elucidate
mechanisms by which IPF patients are more susceptible to lung cancer.
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IDIOPATHIC PULMONARY FIBROSIS:
DIAGNOSIS, PATHOGENESIS AND THE SEARCH FOR A CURE

Idiopathic pulmonary fibrosis (IPF) is a disease with high mortality and of
unknown etiology. Research efforts attempting to elucidate the mechanisms· behind the
development of this lethal fibrotic disease have yet to determine a definitive mechanism.
It is likely that there are multiple mechanisms by which the disease can progress, which

may explain the fact that no single intervention has been proven effective. Therefore,
although researchers and clinicians have been working on this disease for several decades
and this has resulted in improved classification and identification of IPF patients, clinical
outcomes remain unchanged.
It is evident that a narrow approach to furthering knowledge about IPF is not

sufficient. Furthering understanding of this disease by multiple strategies will result in
improved outcomes for these patients faster than by one method alone.

We wanted to

learn more about the presentation and management of these patients as well as the impact
of the disease to healthcare in the

u.s. We hyPothesized that IPF hospitalization rates

and costs were increasing and, if so, this should serve as a justification for further efforts
to address this devastating disease. To test our hypothesis, a multi-step approach was
used. This document analyzes the disease from the standpoint of the patient, and then
expands into current management/treatment options, followed by an analysis of the
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burden of the disease using a national hospital database. It concludes with an investigation of the
cellular effects of oxidant stress, a mechanism implicated in the pathogenesis of IPF and its
consequences. Altogether, this thesis helps to improve knowledge about identification, clinical
management, healthcare burdenlhospitalization statistics and disease pathogenesis.

INTRODUCTION

IPF is a chronic and progressive pulmonary disease characterized by progressive
deterioration of respiratory function due to lung fibrosis. More than 150,000 Americans are
affected by IPF, which is the most common and severe form of the idiopathic interstitial
pneumonias [1]. The progressive fibrosis typical of IPF results in dyspnea that ultimately causes
to respiratory failure (and death) within 3 to 5 years of diagnosis in patients with advanced
disease [2, 3]. The situation is further complicated, since there are no FDA approved drugs to
treat IPF: Lung transplantation and oxygen supplementation are the only treatment options that
have been shown to benefit patients with IPF.
Because of its progressive nature and the lack of effective therapies, an early and accurate
diagnosis of IPF is crucial. A typical patient with IPF is older than 50 years and bibasilar
crackles can be heard during the physical examination.

Imaging studies reveal bilateral

infiltrates with peripheral and basilar predominance, traction bronchiectasis and honeycombing.
Physiological abnormalities with a restrictive pattern are common and often associated with
hypoxemia at rest or during exertion. Lung histology reveals heterogeneous distribution of lung
fibrosis, honeycombing, fibroblastic foci and a paucity of inflammation; this pattern is known as
a pattern of usual interstitial pneumonitis (VIP) [4].
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A diagnosis of IPF is difficult, because the clinical manifestations are similar to other
conditions (e.g., sarcoidosis) and is in part a diagnosis of exclusion [5]. Other conditions that
resemble IPF are interstitial lung diseases related to connective tissue disorders such as
rheumatoid arthritis, systemic lupus erythematosus and progressive systemic sclerosis, and
conditions triggered by environmental exposures, such as chronic hypersensitivity pneumonitis
[6, 7]. An accurate diagnosis of IPF is important considering the differences in prognosis, IPF
shows only a -50% 3-year survival rate. More importantly, no therapies have been proven to
reverse, halt or delay the progression of disease in IPF in large, well-conducted, double-blinded,
placebo-controlled, prospective clinical trials [3, 8].
Diagnosing IPF requires three main criteria: I? The exclusion of other known sources of
interstitial lung diseases (including occupational, environmental, and drug toxicities obtained
through a thorough patient history);

2, A pattern of usual interstitial pneumonia on high-

resolution computed tomography (HRCT) (if a surgical lung biopsy is not available/safe to
obtain); 3, Specific combinations of patterns from HRCT and surgical lung biopsy when both
tests are available. Diagnostic accuracy can be further improved with multidisciplinary talks
. between specialists [3].
Herein, we describe our attempts to understand IPF through the description of a case and
a summary of the treatment/management options currently available to these patients, the
obstacles inherent in developing safe and effective therapies. Afterwards, we discuss the burden
of the disease focusing on hospitalization rates and costs in the U.S. We end by an exploration
of the role of oxidant stress in disease pathogenesis.
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METHODS
The data prepared for this thesis

were generated through independent but

complementary activities: 1) Review of current literature, 2) Exposure to IPF patients at the
clinic, 3) Preparation of a manuscript that describes an IPF patient's presentation, 4) Preparation
of a manuscript that summarizes the current understanding of IPF treatment, 5) Analysis of a
national database to determine the impact of IPF on hospitalization costs, and 6) Investigation of
fibrosis through laboratory work. This work was furthered through interactions with Dr. Roman
and his colleagues at the clinic as well as in the laboratory. The experience culminated with the
presentation of this work at several local and international venues and the publication of
manuscripts in the area of IPF (2 published, 1submitted, 1 in preparation).

1. Literature Review

My initial introduction to the fibrotic lung disease known as IPF began at the start of my
projects with Dr. Roman. I initially devoted my efforts to researching the available literature
related to IPF. I focused my search through PubMed and began looking at review articles and
currently published papers related to IPF. In addition, Dr. Roman helped to focus my search
with suggested articles to read. This led to a better understanding of the disease and also
complimented the time I spent shadowing Dr. Roman at his pulmonary clinic.

2. Clinical Shadowing
The opportunity to add to my literary studies with direct patient interaction was as
rewarding as it was informative. I joined Dr. Roman at his clinic once a week and was able to
4

watch his interaction with his patients, several of whom had IPF. Dr. Roman was an excellent
teacher and helped me to better understand the role of a physician in the management of a
chronic deadly disease. One of the patients that I had a chance to meet served as an example of
an IPF patient for the clinical case report I helped write.

3. Preparation of Clinical Manuscript [9]
To prepare the clinical manuscript describing a patient with IPF, I utilized the physician
notes and laboratory write-ups about the patient. I summarized the relevant information as well
as adding relevant introductory and discussion sections to complement the clinical data.

4. Preparation on Manuscript of IPF Management [10]
My efforts studying the available literature also allowed me to write an article on the
management of IPF in the clinical arena. The article summarized the current treatment options
and strategies for IPF along with an update about the available drugs being tested for the
treatment ofIPF.

5. Analysis of National Database to Determine the Impact of IPF on Hospitalizations
[11]

To address trends related to IPF on a broad scale, I utilized a hospital database known as
the Healthcare Cost and Utilization Project Network (HCUPnet) database.

5

Data available

through the HCUPnet Database provide access to national hospitalization data in the U.S.
between 1993 and 2008. We analyzed data related to ICD-9-CM codes for post inflammatory
pulmonary fibrosis (PPF, ICD-9 code 515) and idiopathic fibrosing alveolitis (IFA, ICD-9 code
516.3) and compared them to those of sarcoidosis (ICD-9 code 135).

6. Investigation of Fibrosis through Laboratory Work

To help address the lack of understanding of disease pathogenesis, I also devoted time to
laboratory research. My efforts focused on working with mouse and human fibroblasts with an
"IPF phenotype". We received several human fibroblast cell lines from patients with IPF. We
found it difficult to work with cell lines from the human patients perhaps due to cell aging. The
cells appeared to be stuck in a state of relative senescence and only some of the cell lines would
grow at any noticeable rate. As a result of this, my work centered on recreating the conditions of
an IPF phenotype in mouse fibroblasts focusing on oxidant stress.

6.a.

Specific laboratory methods

The laboratory experiments necessary for this study involved cell culture, proliferation
assays, Western blot, and an apoptosis assay. Detailed methods for each of these techniques are
described in the section about laboratory work towards identifying targets for intervention later
in this paper.
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BODY OF THESIS
CASE REPORT
[9] - Fioret, D., et aI., A case ofprogressive lungjibrosis. Am J Med Sci, 2011. 341(6): p.
428-30.
A 73-year-old obese white man with a history of high blood pressure came to the
hospital after noticing a lump on his chest.

A biopsy of the lump proved it to be

harmless, but the chest radiograph revealed lung abnormalities that prompted a chest
tomogram and further evaluation. Ultimately, a video-assisted thoracoscopy-guided lung
biopsy was performed that revealed alternating areas of relatively normal lung mixed
with a patchwork of parenchymal tissue involvement by end-stage honeycombing. Areas
of active fibrosis with fibroblastic foci and collagen deposition were also seen in addition
to mild inflammation consistent with a pattern of usual interstitial pneumonia.

The

patient was given a diagnosis of IPF and sent to the University of Louisville Interstitial
Lung Disease Center for further management.
On evaluation, the patient complained of dyspnea on exertion that had been
worsening over the past 2 years.

Mild cough was present, but no other symptoms

suggestive of infection or heart disease were elicited. He had a history of tobacco use
that involved smoking 6 to 8 cigarettes a day for more than 30 years; he quit smoking 22
years ago and was not drinking alcohol or taking alternative medicine therapies. During
questioning about occupational and environmental exposures, the patient acknowledged
working on a farm and being exposed to hay, cattle and other animals on a regular basis
7

throughout his life. Prescribed medications included fluticasone and salmeterol inhalation
once daily, a tablet combining valsartan and hydrochlorothiazide for hypertension,
diltiazem, Turns, and omeprazole for acid indigestion and gastro-esophageal reflux
disease, pentosan polysulfate sodium, acetylsalicylic acid, fish oil and a multivitamin.
The initial physical examination showed normal vital signs with a hemoglobin
oxygen saturation at room air and at rest value of 94% and a respiratory rate of 14
breaths/min. His head examination revealed no lesions, but he had a slightly narrowed
oropharynx.

Examination of the neck revealed no jugular venous distention,

lymphadenopathy or thyromegaly. His heart rate was regular, but showed a systolic 2/6
murmur that was most noticeable in the left sternal border.

The lung examination

revealed bibasilar inspiratory crackles but no ronchi or wheezes.
examination was benign.

The abdominal

Extremities showed no edema, and his fingers showed

borderline clubbing. His electrocardiogram revealed a heart rate of 61 beats/min but was
otherwise normal. A right and left heart catheterization performed by his cardiologist for
atypical chest pain revealed mild disease in the right coronary artery and the circumflex
artery, as well as moderate disease in the mid left anterior descending coronary artery.
The study also revealed evidence of very mild pulmonary hypertension.
During his initial visit, pulmonary function tests revealed no obstruction, but the
total lung capacity was decreased (4.19 L), and the ditIusion lung capacity was severely
reduced (l0.04 40% predicted).

These results were interpreted as consistent with a

severe restrictive ventilator pattern and severe reduction in diffusing capacity. More
importantly, the results were dramatically decreased from those obtained 4 years earlier
which showed a total lung capacity of 5.2 L (78% predicted) and a normal diffusion lung
8

capacity (24.7, 119% predicted). The patient's blood gas showed a pH of 7.429, PC02 of
37.4 and a P02 of 65.

A 6-minute walk test revealed mild hemoglobin oxygen

desaturation to 90%. A chest tomogram revealed fibrotic lung changes with peripheral
distribution and basilar predominance, honeycombing and traction bronchiectasis.
After evaluation of his overall clinical picture, imaging studies and histology, a
diagnosis of IPF was confirmed. Treatment options were discussed, and the patient opted
for participating in a placebo-controlled randomized clinical trial. A few weeks after
inclusion in the trial, the patient developed swelling and a white exudate over his tongue,
considered to be candidiasis, for which he was treated with fluconazole. The exudates
cleared, but the patient had 2 episodes of worsening shortness of breath for which his
primary physician gave him intramuscular steroid injections.
Approximately 2 months after inclusion m the trial, the patient developed
significant shortness of breath on exertion that was persistent and associated with
increased nonproductive cough and significant fatigue.
revealed further deterioration.

Pulmonary function tests

During a 6-minute walk test, his hemoglobin oxygen

saturation (initially at 93 %) dropped to 71 % within 2 minutes. Because of the possibility
of an "exacerbation of IPF," the patient was admitted to the hospital where he underwent
an extensive evaluation.

A chest tomogram using a protocol to detect pUlmonary

embolism revealed the earlier reported changes of fibrosis but no new infiltrates, ground
glass opacification, pleural effusion or other abnormalities, including pulmonary
embolism (Figure 1).

An echocardiogram failed to reveal a cardiac etiology for his

deterioration and sputum, and blood cultures showed no organisms. A bronchoscopy
revealed significant airway erythema and some yellowish secretions. The patient was
9

Figure 1
High-resolution computer tomography (HRCT) in a patient with IPF

Penpheral
Dlstnbunon

Basilar
Predominance

In idiopathic pulmonary fibrosis HRCT typically shows bilateral infiltrates
predominating in the periphery (image A), limited disease in the upper lobes (image B)
and worsening infiltrates toward the lung bases (C). Fibrosis is noted mainly at the bases
where honeycombing is observed (C).
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----------

gIven a diagnosis of severe acute bronchitis and was started on antibiotics and
intravenous steroids. After 3 days hospitalization, the patient was discharged home on
supplemental oxygen and oral antibiotics to be followed in clinic.

After initial

improvement, the patient has continued to deteriorate with worsening dyspnea on
exertion and has increased requirements for oxygen supplementation.

DISCUSSION
IPF has received a great deal of attention lately due to the recognition that this

deadly illness affects more than 150,000 Americans, that its incidence is increasing, [1]
and by the increased number of clinical trials available to patients. Despite the above,
this case highlights many of the difficulties inherent in the diagnosis and management of
patients with IPF. Often, and despite increased awareness about the disease, patients with
IPF have symptoms for more than 2 years before a diagnosis is made. Diagnosis is

delayed because of the slow insidious course of the disease in an aging population (IPF
occurs mainly in subjects older than 50 years) that often has an increased frequency of
exercise-limiting conditions, such as heart disease [12].
An early diagnosis of IPF is important, given differences in prognosis and in
management with earlier detection. The 3-year survival rate for IPF is

~50%,

and it has

no cure, whereas survival is better in other idiopathic interstitial pneumonias and related
interstitial disorders [2]-[3].

Also, there is no effective therapy for IPF, whereas

immunosuppression may be effective in other conditions associated with lung
inflammation and fibrosis [12]-[13].
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An accurate diagnosis of IPF requires a thorough patient history and physical
examination, and a careful analysis of diagnostic examinations and imaging studies. The
patient history should include job history, smoking and drinking habits, associated
diseases, family medical history and any exposure to environmental or occupational
irritants such as metal dusts, paints and animals/pets. The latter is especially important as
these exposures may cause conditions that could be confused with IPF such as chronic
hypersensitivity pneumonitis, a disorder included in the differential diagnosis of our case
[3].
A thorough evaluation for autoimmune causes of pulmonary fibrosis that includes
scleroderma, rheumatoid arthritis and systemic lupus erythematosus should be
undertaken.

The clinical history is most critical here, and a screening antinuclear

antibody and rheumatoid factor serology, among other serologies, should be obtained [3].
The physical examination is not particularly revealing, except for the presence of
bibasilar crackles, which sometimes leads to the erroneous diagnosis of congestive heart
failure [14].

Digital clubbing is relatively frequent (25-50% of patients) but is not

specific to, or necessary for, the diagnosis of IPF [12]. Pulmonary function tests usually
reveal a restrictive pattern and marked decrease in gas transfer as measured by the
diffusing capacity for carbon monoxide.

Hemoglobin oxygen saturation should be

evaluated both at rest and exertion as abnormalities may only be detected during exertion
during the early stages of the disease.
Chest radiography is useful, but it may overlook significant changes. It typically
shows bilateral reticular infiltrates (typically peripheral and basilar) and small lung

12

volumes. Upper lobe predominance or the presence of other findings such as significant
lymphadenopathy, pleural effusions and/or calcifications and cardiomegaly should point
to alternative diagnoses. A high-resolution chest tomogram (HRCT) is crucial for the
evaluation of subjects with interstitial lung disease [3]. In IPF, typical chest tomography
findings include bilateral peripheral infiltrates with basilar predominance associated with
traction bronchiectasis and, often, honeycombing. In the right clinical setting, and if the
fibrosis is considered idiopathic, a chest tomogram with the above findings is sufficient to
confirm the diagnosis of IPF [15]. In the absence of the typical findings on HRCT, and
especially if ground glass opacification is present, a surgical biopsy might be necessary
for establishing the diagnosis.

However, the benefits of a surgical biopsy must be

weighed against the risk of the procedure, and the age of this population and
accompanying medical conditions such as heart disease, hypertension and diabetes must
be taken into consideration.
Bronchoscopy, bronchoalveolar lavage and transbronchiallung biopsy are helpful
to rule out infection and granulomatous disorders (e.g., sarcoidosis) but rarely provide
sufficient material to evaluate histological patterns that is crucial for an accurate
diagnosis of the idiopathic interstitial pneumonias. It is for this reason that a surgical
biopsy is often considered for a definitive diagnosis [16-18]. As in our patient, histology
shows a pattern of usual interstitial pneumonitis, which is characterized by heterogeneous
distribution of fibrosis, paucity of inflammation, the presence of fibroblastic foci and
honeycombing. However, this histological pattern is not entirely specific and may be
elusive even in the hands of the most experienced pathologists [19]. Figure 2
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Figure 2

Evaluation schematic for patients suspected of interstitial lung disease (lLD)
History and Physical
emphasize "dust and drug" history

lU!Exam
crackles: stigmata of autoimmune disease

J

LabOratory
Comp panel: CBC with difT; ANA. RF. other serologies

PFT
Spirometry. Lung volumes.
OLCO

Radiology
PA and lateral, HRCT;

l

Refer

Tissue

SLB
JPF and other liPs

TBLB
Granulomatous ILO

The pulmonary history is paramount in the evaluation oflLD. Initial laboratory work
should include a complete metabolic profile (Comp panel) and antinuclear antibody
(ANA) and rheumatoid factor (RF) screen. A postero-anterior (P A) and lateral chest film
will define the diffuse bilateral abnormalities typical of the ILD, and the high-resolution
computerized tomogram (HRCT) adds specificity and can resolve abnormalities not seen
on plain film. When tissue is needed for diagnosis and management decisions, the patient
is referred for biopsy. Transbronchiallung biopsy (TBLB) is the procedure of choice
when there is suspicion of granulomatous disorder such as sarcoidosis. Surgical lung
biopsy (SLB) is preferred for diffuse nongranulomatous ILD such as idiopathic
pulmonary fibrosis (IPF) or the other idiopathic interstitial pneumonias (lIPs).
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demonstrates a relatively straightforward evaluation for interstitial lung diseases such as
IPF.
In general, IPF is a slowly progressive disorder that manifests as progressive
dyspnea on exertion and exercise intolerance culminating after a few years in respiratory
failure. However, in a minority of patients (perhaps 15%), the natural history of the
disease differs. In such cases, IPF may progress through unexpected episodes of
deterioration characterized by acute worsening of exercise intolerance (usually within 30
days before medical evaluation), decreased oxygen hemoglobin saturation and HRCT
with new infiltrates and/or ground glass opacification [3]. After exclusion of other causes
(e.g., infection, pulmonary emboli and congestive heart failure), this rapid deterioration is
likely related to what has been termed as "exacerbation of IPF ," an entity that carries a
worse prognosis, due to faster progression of disease [20, 21]. As was the case in our
patient, and because of its importance, patients showing deterioration should be evaluated
for exacerbation of IPF. Because IPF is considered a diagnosis of exclusion, tests should
be ordered to rule out other conditions such as infection (often by bronchoscopy),
thromboembolic disease or congestive heart failure.
Despite the lack of proven effective therapies, there is still much that can be done
for patients with IPF. Initially, effort should be given to confirming the diagnosis by
reviewing all data available, and by evaluating imaging studies and histology, if
available. The need for oxygen supplementation, evaluation for pulmonary rehabilitation
and candidacy for lung transplantation (an effective but limited surgical option) should be
considered early. Importantly, education about the disease and its prognosis should be
provided, and avoidance of toxic agents (e.g., tobacco) should be encouraged. An early
15

evaluation for related conditions is also important including pulmonary hypertension
[22]. As there are no proven effective medical therapies for IPF, patients should be
considered for inclusion in clinical trials.

16

MANAGEMENT OF IDIOPATHIC PULMONARY FIBROSIS [10]

CHALLENGES IN TRANSLATING PRECLINICAL TRIALS
TO EFFECTIVE DRUG THERAPIES

Before the 1990s, many patients with pulmonary fibrosis of unknown etiology
were diagnosed with IPF and were often treated with high doses of steroids. However,
although some patients showed improvement, others showed continuing deterioration
despite similar clinical presentation and treatment.

This led many to conclude that

patients initially diagnosed with IPF actually suffered from a variety of conditions; some
steroid responsive, others less responsive [23]. This new understanding prompted the
careful analysis of the histology of subjects diagnosed with IPF, which ultimately led to
the classification of the idiopathic interstitial pneumonias, of which IPF is a member [12].
In contrast to other idiopathic interstitial pneumonias, IPF shows a characteristic
histological pattern termed usual interstitial pneumonia (VIP). Later clinical studies that
considered histological diagnosis showed that patients diagnosed with IPF in association
with histology of VIP represented the most common subgroup of patients with idiopathic
interstitial pneumonias and, importantly, the one with the worse prognosis. Specifically,
although no well-controlled prospective studies were conducted, a general consensus
grew about the lack of responsiveness of IPF to steroids.

Despite the above, and

considering the lack of effective therapies, many patients with IPF are currently treated
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with steroids and/or other immunosuppressants pending the identification of new
therapies. It is for this reason that a stronger emphasis is being placed on the conduct of
clinical trials designed to evaluate prospectively the safety and effectiveness of new
therapies [8]. To date, these efforts have failed to unveil a "magic bullet" but much has
been learned through these trials, which have helped shape the standard of care for this
condition.

THE SEARCH FOR EFFECTIVE THERAPIES IN IPF

There are a variety of new studies testing treatment options for IPF.
Clinicaltrials.gov, a registry of federally and privately supported clinical trials, lists 90
currently

recruiting

(http://clinicaltrials.gov).

(active)

or

recently

completed

studies

of

IPF

The trials listed show how changing ideas about the

pathogenesis of this condition have shaped our approach to therapy. For example, it was
originally thought that IPF was caused by relentless inflammation, and this explains why
early clinical trials often involved anti-inflammatory agents such as corticosteroids.
These early studies were often flawed by misclassification of patients with or without
IPF, as well as the lack of placebo control groups, but recent publications suggest that
there is no apparent benefit of corticosteroid use for treatment of IPF [23]. Subsequent
studies testing other anti-inflammatory agents (e.g., etanercept, interferon-y and
interferon-~),

among others, have also failed to show much benefit [8, 24, 25] (Tables 1-

3).
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Table 1

Drugs found to be ineffective in the treatment of IPF

Medications

Results

Study Comments

IFN-y* vs. placebo [25]

No increase in survival

New study testing IFN-y by
an inhaled route is planned

Bosentan vs. placebo [26]

No change in 6MWT* seen New study is testing to see
whether Bosentan delays
time until death/decreases
lung deterioration

Imatinib vs. placebo [27]

Negative study

Prednisolone + IFN-y
Inconclusive results
vs. Prednisolone + Colchicine [28]
NAC*, azathioprine,
Increased mortality vs.
+ prednisone vs. placebo [29] placebo group

Trial testing NAC alone vs.
placebo undergoing

Warfarin vs. placebo [30]

Warfarin appeared to
increase mortality due to
respiratory worsening.
Didn't include patients
requiring warfarin for nonIPF related treatments.

Negative study

*IFN, interferon; 6MWT, six-minute walk test; NAC, N-acetylcysteine
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Table 2

Drugs requiring further investigation in the treatment of IPF

Medications

Results

Study Comments

Etanercept vs. placebo [24]

Improved FVC* and DLco*

Original study did not reach primary end point

Prednisone + azathioprine vs.
prednisone + placebo [31]

Trend to improved resting arterial
02, small increase in survival

Small test group, only a trend toward
improvement, changes not significant

Prednisolone + anticoagulant vs.
prednisolone [32]

Significant increase in survival

Not a double-blinded study. Diagnostic criteria
used were not standard

Pirfenidone vs. placebo [33]

Improved lung function variables

Primary end points for study were atypical and
were not met. 22% of the patients stopped
participating in the study

N

o

N-acetylcysteine vs. Bromhexine [34]

No improvement in pulmonary
function tests or quality of life
*DLco, diffusing capacity for carbon monoxide; FVC, forced vital capacity

May delay disease progression in N-acetylcysteine
group

Table 3

Drugs considered to have some efficacy but require further testing

N

.....

Medications

Results

Study Comments

Pirfenidone vs. placebo [35]

Less of a decrease in %FVC*,
Fewer deaths in high dose group

Approved treatment in Japan, more side effects in
high dose group. No FDA * approval

Prednisolone +IFN-y* vs. prednisolone [36] Significant improvement in lung
function for combination drug
patients

N= 18, significant improvement atypical.
Retesting with a larger patient group advisable
and include a double-blinded, placebo control

Azathioprine, prednisone, + NAC* vs.
Decreased decline in FVC and
Azathioprine, prednisolone, + placebo [37] gas transfer for CO* deterioration
in the non-placebo group

Lack of a placebo-only control group

*IFN, interferon; NAC, N-acetylcysteine; FVC, forced vital capacity; CO, carbon monoxide; FDA, food and drug administration

Knowledge has accumulated suggesting that tissue fibrosis can occur without
inflammation or dissociated from it. In fact, in cases where IPF is suspected, significant
tissue inflammation should lead clinicians to search for an alternative diagnosis. Despite
the above, a statement published by the American Thoracic Society/European
Respiratory Society in 2000 suggested the use of low-dose prednisone (a corticosteroid)
with azathioprine (an immunosuppressant) for treatment. This combination became a
standard therapy largely due to the lack of available treatment options. However, in
2008, the Idiopathic Pulmonary Fibrosis International Group Exploring N-acetylcysteine
I Annual Study tested the addition of an antioxidant, N-acety1cysteine, to the standard
regimen [37].

Although this study showed delays in the progression of IPF, it was

heavily criticized for its small size and for the lack of a control group. Nevertheless,
despite the lack of proven effectiveness, this new, largely untested, treatment regimen
including N-acety1cysteine (NAC) evolved as the standard of care.

Unfortunately, a

recent randomized, double-blinded, placebo-controlled trial testing the effect of this
combination therapy (prednisone, azathioprine, and NAC) was stopped prematurely due
to an increased rate of death in the combination group versus placebo (8 vs. 1 patients).
In addition there was no physiological or clinical benefit seen in the combination group
and combination therapy patients had increased adverse events [29]. However, a separate
study comparing the use of only NAC versus placebo is still ongoing [29]. A similar
situation has recently evolved regarding the use of warfarin (an anticoagulant) in the
treatment of IPF [38]. Previous findings had suggested a potential benefit of warfarin in
a subset of patients (receiving a weak negative recommendation [3]), however, recent
evidence has shown that warfarin therapy shows no clinical efficacy and is associated
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with an increased risk of mortality (excluding IPF patients that required anticoagulation
for non-IPF related reasons) [30].
As other concepts about IPF pathogenesis emerged, phase I, phase II and phase III
clinical trials have been conducted to test their accuracy. In general, the agents tested
show benefits when examined in animal models of lung fibrosis. These include inhibitors
of fibrotic growth factors (e.g., connective tissue growth factor, transforming growth
factor

~

and platelet-derived growth factor), endothelin receptor antagonists (e.g.,

bosentan), inhibitors of kinases (e.g., imatinib), anticoagulants (warfarin) and
antifibrotics (e.g., pirfenidone) [8, 26, 27, 32, 39].

Unfortunately, benefits have not

always been observed in these studies, improved survival has not been demonstrated and
much controversy still remains. However, the data generated suggest that some of these
approaches should be considered further. More importantly, these studies have prompted
the generation of new and testable hypotheses about IPF pathogenesis.
There are several important factors to consider when designing a new study. Of
particular importance is the use of a placebo-only control group. Also, a standard or at
least a minimum criterion for primary endpoints should be established.

Although

enhanced survival is the most robust endpoint for a trial, other factors such as a change in
forced vital capacity or performance on 6-minute walk test and possibly the use of
biomarkers (once suitable markers are identified) should be considered for use as primary
and secondary endpoints.
Clinical studies are often limited by a small sample size, especially in the case of
a disease such as IPF. In part, the limited number of patients available for participation in
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trials is addressed by involving multicenter clinical trials.

Collaboration between

different centers can and should be encouraged. Recruitment criteria are established and
include confirmation of a diagnosis of IPF in all the participating patients. Until effective
treatments are found, attention should be given to the treatment of comorbid conditions.
A recent clinical trial tested the ability of Sildenafil, a phosphodiesterase-5 inhibitor, to
improve patients with advanced IPF. The primary outcome was not achieved; however,
small but significant differences in arterial oxygenation, carbon monoxide diffusion
capacity, degree of dyspnea and measures of quality of life were seen [13].
IPF, as the name suggests, has no known cause. Nevertheless there are several
factors that are associated with a greater risk for disease development and progression
including male gender, genetic mutations, smoking, and gastrointestinal reflux disease [3,
40-42]. In certain subjects, pulmonary fibrosis develops from known pro-fibrotic stimuli
such as allergens, asbestos, and drugs, or is associated with chronic inflammatory
conditions such as connective tissue disorders [43,44].

THE IMPACT OF GENETICS

A genetic association of IPF is seen in less than 5% of all patients with the disease
although higher numbers

(~20%)

have been reported in some smaller cases. The familial

form, as defined by affecting two or more members of the same biological family, is
histologically and clinically identical to the sporadic form of IPF [45]. Evidence now
suggests that mutations in two separate gene pathways both lead to the common
phenotype of IPF. These mutations occur in the genes encoding lung surfactant proteins
24

C and A2 which lead to increased endoplasmic reticulum stress in type 2 alveolar
epithelial cells (these mutations are found almost exclusively in familial cases of IPF).
The other mutations occur in genes that encode telomerase (TERT and TERC) which are
believed to cause IPF by the shortening of telomere lengths in lung stem cells (the
majority of these cases are found in familial IPF). Interestingly, short telomere lengths
are found in both familial and sporadic IPF even in the absence of the telomerase
mutation. This suggests a connection with the age-related prevalence of IPF [46]. It is
important to note that the surfactant and telomerase mutations account only for ~ 15-20%
of all familial IPF cases. Thus, there are likely several other genes responsible for the
development ofIPF. In addition, although these mutations are significantly less prevalent
in sporadic IPF, the pathways that are involved with these genes are often dysfunctional
[47].
Race appears to playa role in patient survival and outcome.
survival rate was found to be

~45%

for Non-Hispanic whites versus

The three-year
~35%

for Non-

Hispanic Blacks and Hispanics [48]. In addition, race has an effect on survival following
lung transplantation.

Black and Hispanic patients with advanced IPF have shorter

survival times following lung transplantation. The 2-year survival estimate for Blacks
and Hispanics was 30% versus 82% in Whites and Asians [49].

OTHER IMPORTANT CONSIDERATIONS REGARDING IPF MANAGEMENT
The lack of Federal Drug Administration-approved medications for the treatment
of IPF does not mean that physicians have nothing to offer in this setting. This is far
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from the case considering that lung transplantation and oxygen supplementation have
been shown to extend survival in these patients [50].

In addition, these and other

interventions can improve quality of life. Thus, it is important that patients suspected
and/or diagnosed with IPF be referred to centers with expertise in this field, so that
patients are evaluated thoroughly and appropriate treatment strategies are considered.
The general management of IPF is summarized in Figure 3 and specific interventions are
described later.

OXYGEN THERAPY
As the disease progresses, IPF causes dyspnea on exertion mainly due to increases
in the work of breathing and alterations in gas exchange capacity and hypoxemia. In this
setting, supplemental oxygen therapy is useful as it may diminish dyspnea and improve
exercise tolerance. However, the need for supplemental oxygen may be missed if
patients have only resting arterial blood gas or oxygen saturation measurements. Patients
should be tested for supplemental oxygen using a 6-minute walk test, a test that evaluates
distance walked and hemoglobin oxygen saturation during exertion. Oxygen
supplementation should be considered in patients who show hemoglobin oxygen
de saturation below 88% (or P02 <55 mm Hg) [3]. Oxygen can be given nasally, through
a mask or in some cases by transtracheal delivery. The amount of time required to use
the oxygen delivery system depends on the condition of the patient's disease. Initially, it
may only be required during strenuous activities, but as the disease progresses, it may be
required more often or continuously. Oxygen may be supplied by a stationary
concentrator for home use and portable tanks of compressed gas. When higher flow rates
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Figure 3

General management of patients with IPF

Managen1ent of IPF
Confirm diagnosis
Educate about
prognosis

Consider if candidate
for pulmonary rehabilitation
Determine candidacy
for lung transplantation

Stop offenders
Evaluate for
oxygen
supplementation

Evaluate other problems
(e.g., cough, pulmonary
hypertensio n)
Consider clinical trial

Once identified, patients suspected of IPF should be evaluated to confirm the diagnosis.
If confirmed, attention should be given to education and evaluation for the need for
oxygen supplementation and candidacy for pulmonary rehabilitation and lung
transplantation. Control of cough and early detection of associated conditions (eg,
pulmonary hypertension) should be considered. Finally, until an effective drug becomes
available, patients should consider participating in clinical trials.
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(4-5 Llmin) are needed at rest or long portable times are required, a liquid oxygen setup
is appropriate.

PULMONARY REHABILITATION

The benefits of physical rehabilitation have not been widely studied; however,
pulmonary rehabilitation is considered important in building and maintaining aerobic and
physical fitness and treatment of dyspnea in select patients [51].

Training usually

involves breathing exercises, physical conditioning and anxiety and depression
management. Similar to the necessity of talking to patients who convey an understanding
of their treatment options, pulmonary rehabilitation is essential in helping patients
manage their condition and maintain the highest quality of life possible.
COUGH SUPPRESSION

One of the most distressing and difficult-to-treat consequences of IPF is cough.
Cough has a measureable impact on the quality of life and correlates with cough
frequency as determined by cough counts or perception of cough frequency by patients
[52]. The mechanisms of cough in IPF are not well understood, but the triggers for this
symptom reside in the airways as demonstrated by cough challenge tests using capsaicin.
Patients with IPF show a 30-fold increased sensitivity (i.e., 30 times lower dose versus
healthy subjects) to cough inducing levels of capsaicin [53]. Even though chronic cough
is a major symptom of IPF, approximately one half of the cases of chronic cough in IPF
can be attributed to more common causes such as hyperresponsive airways,
gastroesophageal reflux and rhinosinusitis [54].

The management of cough in IPF

should, therefore, include a careful evaluation for the other causes of chronic cough.
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Treatment of chronic cough due to IPF is difficult, and common treatments often fail.
Ironically, systemic steroids that have no impact on the course of IPF may be effective in
mitigating cough in this disease [55].

LUNG TRANSPLANTATION

Lung transplantation is the closest option to a cure for IPF; however, there are
several limitations to this treatment option.

IPF is a disease that is predominantly

associated with older age with the median age being 66 years at diagnosis [56].
Advanced age, along with the frequency of comorbid conditions (i.e., pulmonary arterial
hypertension, cardiac disease) increase the complications and risks associated with
surgery [57].

This also results in worse outcomes for IPF patients following

transplantation compared with other respiratory conditions [58].

SUMMARY

IPF is a chronic disease characterized by progressive lung fibrosis. Studies in
animals have unveiled drugs that might be helpful in preventing lung fibrosis.
Unfortunately, these studies have not been duplicated in humans, and, to date, clinical
trials have failed to unveil a drug capable of improving survival. Consequently, lung
transplantation and oxygen supplementation remain the only therapeutic options capable
of improving survival in patients with IPF. Despite this, there is still much that can be
done to improve the quality of life in these patients including physical rehabilitation and
control of cough (Figure 3). Also, patients may benefit from the early detection and
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treatment of secondary problems (e.g., pulmonary hypertension).

Until a therapy is

found, patients with IPF are encouraged to engage in well-conducted clinical trials that
may someday unveil a safe and effective treatment for this devastating disease.
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IMPACT TO HEALTHCARE
National Database (Health care Cost and Utilization Project)
The burden placed on the healthcare system by patients with IPF is extensive.
IPF patients are some of the most costly patients to treat during advanced stages of the
disease.

Limited treatment options and the lack of FDA approved drugs make

understanding the impact of IPF patients to the healthcare system essential. In order to
bridge the knowledge gap between the clinical arena and the costs associated with
treating patients at the national level an epidemiological study using a national healthcare
database was undertaken focusing on hospitalization rates and costs.

HOSPITALIZATION RATES, LENGTH OF STAY, MORTALITY AND COSTS
OF IPF IN THE UNITED STATES
The incidence of IPF appears to be increasing although questions remain as to
whether this is related to increased awareness or a true change in incidence ofthe disease.
This has been influenced by the increased use of high-resolution computed tomography
scans, which became more commonplace since the 1990s and provided an easier, more
economical, and more accurate means of diagnosing IPF and related pulmonary disorders
[59].

Additionally, the publication by the American Thoracic Society and European

Respiratory Society (ATS/ERS) of an international consensus statement of the diagnosis
and treatment guidelines for IPF in 2000 [60] and of idiopathic interstitial pneumonias in
2002 [12] likely increased physician awareness and accurate diagnosis of the disease.
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Current information about the morbidity and mortality of pulmonary fibrosis is needed.
Others have reported a seasonal variation in mortality due to IPF (mortality is the highest
during the winter) [61] and have reported the rate of mortality increasing
between 1992 and 2000; the average age- and sex-adjusted mortality rate was 50.8 per
1,000,000 people [62]. Furthermore, among those with IPF, Blacks are less likely to die
from IPF than Whites, whereas Hispanics are more likely to die than Whites [63].
Our analysis focuses on hospital admissions, in-hospital mortality, length of stay,
and charges associated with pulmonary fibrosis. For this, we utilized a public database
containing hospitalization information known as the Healthcare Cost and Utilization
Project (HCUP) Public Database.

METHODS

THE HCUP DATABASE
Data available through HCUP provide access to a family of healthcare databases.
These include the Nationwide Inpatient Sample (NIS), which contains inpatient data from
a national sample of over 1,000 hospitals in the United States as well as the State
Inpatient Database (SID) that contains inpatient discharge abstracts from participating
states. Data from the databases are provided from 1988 to the present date [11]. The NIS
is the largest all-payer inpatient care database in the United States and contains data from
~8

million hospital stays yearly. The NIS contains data from 1,050 hospitals located in

44 states and approximates a 20% stratified sample of U.S. community hospitals. The
SID contains the inpatient discharge abstracts from participating states.
encompasses ~90% of all U.S. community hospital discharges.

32

The SID

PATIENT COHORT AND DATA ANALYSIS
Using the HCUPnet Database, we analyzed data related to ICD-9-CM codes for
post inflammatory pulmonary fibrosis (PPF, ICD-9 code 515), idiopathic fibrosing
alveolitis (IFA, ICD-9 code 516.3), and sarcoidosis (ICD-9 code 135). We compared
different parameters available for each disease (e.g., charges, length of stay, mortality,
procedures, and diagnoses). We investigated changes over time for the United States (for
those states participating in the database) between 1993 and 2008. Geographic location
was defined as Northeast, South, Midwest, and West based on U.S. census regions.
Classification of co-morbidities was based on the patient's secondary diagnoses.

RESULTS

HOSPITAL ADMISSIONS
Analysis of the HCUPnet Database revealed an increase in the number of hospital
discharges nationwide between 1993 and 2008 with an upsurge by the tum of the century
(Figure 4A). During the same time period, a steady increase in hospital admissions was
noted for patients with a principal diagnosis of PPF, doubling in the same time period and
reached close to 30,000 admissions per year in 2008; these changes averaged to a 4.9%
increase per year (Figure 4B). In contrast, admissions related to IF A were relatively
stable, declined early in the past decade to 3,513 admissions per year in 2008. For
comparison, hospital admissions related to sarcoidosis have increased on average
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Figure 4
Hospital Discharges

A

.E

42

'"~

40

.r:.
~

38

Q '"
!! 5

36

C'\1

's.=
'"o .~
J:

34

'0

32

.c
E

30

...IV
:::s

1993

Z

B

40000
n;

30000

.~

Q.

..... AII Conditions

1997

2001

200S

2009

2001

200S

2009

->-PPF
...... Sarcoidosls
-o-IFA

'"o IV'"

J:
-

e.o

C'\1
O.r:.
... u
IV .!a

20000

.co
10000
E
:::s

Z

o
1993

1997

Figure 4 I A. Increase in the number of hospital discharges nationwide. B. Hospital
discharges have doubled for PPF. Discharges for IF A have decreased, while sarcoidosis
discharges have increased 1.9%/year on average.
IF A, idiopathic fibrosing alveolitis; PPF, postinflammatory pulmonary fibrosis
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1.9%/year, reaching 7,588 admissions

In

performed

lobectomy

in

these

patients

with

2008.

Table 5 lists the top procedures
or

pneumonectomy,

diagnostic

bronchoscopy/biopsy of bronchus and related procedures, and intubation/mechanical
ventilation at the top of the list. Importantly, a significant percentage of patients admitted
with a primary diagnosis of PPF, IF A or sarcoidosis also suffered from other important
medical conditions, such as essential hypertension, hyperlipidemia, diabetes, and
coronary atherosclerosis (Table 6). The database also included information related to
adverse effects of medical drugs (E code), showed that up to 16% of patients hospitalized
for IFA suffered from this problem, which was associated with 18.63% mortality; no
information about adverse effects of medical drugs was provided for PPF or sarcoidosis.
When the HCUPnet Database was analyzed to evaluate the reasons for
hospitalization, we noted that, in general, patients were hospitalized with primary
diagnoses other than PPF, IF A or sarcoidosis.

For example, there were many more

patients hospitalized with a secondary diagnosis of IF A than those hospitalized with IF A
as a primary diagnosis (Figure 5A). Discharges of IF A patients where IFA was not the
principal diagnosis decreased significantly between 2003 and 2004 and reached 15,105
by 2008.

Overall, during the 15 year period examined, there was an increase in

hospitalizations for patients with PPF, where PPF was not the principal diagnosis; from
150,000 in 1993 to 250,000 in 2008. As observed for PPF, hospitalizations of patients
with secondary diagnosis of sarcoidosis increased steadily in the same time period
tripling since 1993 (28,638 hospitalizations) to 74,630 admissions by 2008 (Figure 5C).
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Table 5
Primary procedures for patients hospitalized with IF A *, PPF*, and sarcoidosis (2009)**
CCS
Code

Primary Procedure

Principal Diagnosis: % Total Discharges (% Mortality)
PPF
Sarcoidosis
IFA

36

Lobectomy or
Pneumonectomy

9.0

20.7 (1.9)

5.1

37

Diagnostic Bronchoscopy
and Biopsy of Bronchus

5.4

6.8

11.5

38

Other Diagnostic Procedures
on Lung and Bronchus

5.6

216

Respiratory Intubation and
Mechanical Ventilation

40

Other Diag. Procedures of
Respiratory Tract + Mediastinum

5.8 (67.1)

8.8(3.1)

2.0

4.1 (49.2)

3.1

0.5

8.8

Note: A 2::5% discharges was used as the threshold for inclusion.

* IF A, idiopathic fibrosing alveolitis; PPF, postinflammatory pulmonary fibrosis
**[11]
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Table 6
Secondary diagnoses for Qatients hosQitalized with idioQathic fibrosing alveolitis (IF A)*,
Qostinflammatory Qulmonary fibrosis(PPF}* or sarcoidosis (2009) [11]
CCS
Code

Secondary Diagnosis

Principal Diagnosis: % of Total Discharges (% Mortality)
IFA*
PPF*
Sarcoidosis

131

Respiratory Failure,
Insufficiency, Arrest (adult)

47.8 (25.2)

30.1 (18.2)

14.5 (6.3)

98

Essential Hypertension

44.0 (14.1)

42.6 (5.8)

39.7

53

Hyperlipidemia

36.3 (15.6)

28.2(5.1)

18.3

127

Chronic Obstructive
35.3 (9.7)
Pulmonary Disease + Bronchiectasis

34.4 (6.2)

18.4

49

Diabetes Mellitus
Without Complication

31.5 (12.1)

24.1 (7.6)

23.2

101

Coronary Atherosclerosis

31 (16.1)

24.5 (7.6)

257

Other Aftercare

29.5 (17.5)

20.3 (13.7)

106

Cardiac Dysrhythmias

28.8 (23.2)

21.5 (11.2)

663

Screening/History of Mental
Health and Substance Abuse

28.5 (14.7)

29.9 (4.9)

259

Residual Codes, Unclassified

27.8 (15.1)

25.5 (6.4)

27.2

103

Pulmonary Heart Disease

27.7 (15.8)

17.4 (12.8)

13.4

138

Esophageal Disorders

26.7 (12.7)

23 (5.3)

108

Congestive Heart Failure,
Non-hypertensive

26.4 (12.7)

23.1 (11.4)

13.1

55

Fluid and electrolyte disorders

26 (25)

20.0 (13.5)

17.7

122

Pneumonia (not TB/STDs)

25.2 (22.6)

18.7 (16.4)

14.6

244

Other Injuries/Conditions
Due to External Causes

24.9 (17.5)

18.3 (11.5)

133

Other Lower Respiratory
Disease

23.1 (13.6)

16.5 (7.5)

65

59

Anemia

21.7 (21.2)

18.2 (9.4)

17.6

2617

E Codes: Adverse Effects
of Medical Drugs

16.1 (18.6)

37

13.3
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Figure 5 I A. Discharges of IF A patients where IF A was not the principal diagnosis
decreased significantly between 2003 and 2004. B. Discharges where PPF was not the
principal diagnosis increased overall from 150,000 to 250,000. C. Discharges for
sarcoidosis have increased from 3,513 to 7,588.
IF A, idiopathic fibrosing alveolitis; PPF, postinflammatory pulmonary fibrosis
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The above data suggested that patients with diagnosis of PPF, IF A or sarcoidosis
are often admitted due to other conditions. Table 7 lists the top primary diagnoses for
which patients were admitted, pneumonia, respiratory failure, chronic obstructive
pulmonary disease, congestive heart failure and septicemia led the list. When data were
available for an individual diagnosis (i.e., pneumonia), it was evident that subjects with
IF A experienced the highest mortality from these conditions followed by PPF. Also,
subjects with IF A and PPF showed the highest incidence for critical secondary diagnoses,
such as respiratory failure.

LENGTH OF STAY
Length of stay during hospitalization for all conditions decreased steadily in the mid1990s and stabilized at 4.6 days by 2009 (Figure 6A). Length of stay for PPF, IFA and
sarcoidosis were higher (1-3 days) than the average for all conditions during all years of
this analysis. For PPF, length of stay decreased during the mid-1990s and remained
relatively stable at 6 days.

On the other hand, length of stay for IF A was the highest of

this group starting at 9.7 in 1993, decreasing thereafter, only to increase again in 2007
with an average length of stay of 9.3 days by 2008. For sarcoidosis, length of stay
declined progressively from 7.5 days in 1993 to 6.2 days by 2008. As shown in Figure
6B-D, length of stay for the three diagnoses did not appear to differ significantly based on
region except for IF A for which the length of stay increased dramatically in 2007 with a
return to baseline a year later in the Northwest region.
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Table 7
Primary diagnoses for patients hospitalized with secondary diagnoses of IF A *, PPF*, or
sarcoidosis (2009)**
CCS
Code

Primary Diagnosis

Secondary Diagnosis: % of Total Discharges (%Mortality)
IF A
PPF
Sarcoidosis

122

Pneumonia

14.6 (10.4)

12.8 (7.1)

6.5 (1.9)

131

Respiratory Failure,
Insufficiency, Arrest (adult)

10.5 (31.7)

6.2 (21.7)

2.6 (11.2)

127

Chronic Obstructive Pulmonary
Disease and Bronchiectasis

8.1

9.8 (2.2)

3.7

108

Congestive Heart Failure,
Non-hypertensive

7.0

8.2 (5.4)

4.4 (3.2)

2

Septicemia (except in labor)

106

Cardiac Dysrhythmias

100
128

5.0 (25.2)

4.2 (22.7)

3.1 (10.3)

2.9

3.1 (3.3)

2.8

Acute Myocardial Infarction

2.2

2.2 (9.3)

Asthma

l.5

2.0

*IFA, Idiopathic Fibrosing Alveolitis; PPF, Postinflammatory Pulmonary Fibrosis
**[11]
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Figure 6 Length of Stay
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Figure 6 I A. Length of stay during hospitalization for all conditions decreased steadily in the mid-1990s and stabilized at 4.6 days by
2009. PPF and sarcoidosis had similar average lengths of stay, whereas IFA patients had the longest (-9 days). B-C. Length of stay for
the three diagnoses did not appear to differ significantly based on region except for IF A for which the length of stay increased
dramatically in 2007 with a return to baseline a year later in the Northwest region.
IF A, idiopathic fibrosing alveolitis; PPF, postintlammatory pulmonary fibrosis; Region is defined by the U.S. Census regions

The length of stay was also analyzed based on the payer (Figure 7A-C). For the duration
of the time studied, patients paying with private insurance had the shortest length of stay
for patients with PPF and sarcoidosis

(~5

days for each condition). The length of stay

varied for IF A, although Medicaid patients generally stayed the longest time in the
hospital

(~1 0

days). Medicaid patients with PPF also had the longest length of stay as

compared to other payer types

(~7

days). Length of stay did not appear to differ

significantly when the data were analyzed for gender (Figure SA-C). However gender
did play a role on percent hospital discharges. We saw more female discharges from
1997 -2002 for IF A, but these values switched in recent years with males comprising the
majority of hospital discharges (Figure 9A). For PPF and sarcoidosis, there was a ~ 10 to
35%, respectively, greater percent of female discharges compared to males (Figure 9BC). IF A discharges by gender were not as distinct.
We then determined where the patients were sent after their hospitalization. As
depicted in Figure 10, most patients with PPF
(~SO%)

(~65%),

IFA (50%), and sarcoidosis

demonstrated a 'routine discharge' indicating that they returned home with

routine care. However, this number decreased with time, and by 2009, over 15% of
patients hospitalized for PPF and IF A were discharged to home health care (Figure lOB).
A smaller percentage was discharged to another short-term hospital (Figure 10C). For
PPF and IF A, between 10% and 15% of patients were discharged to another institution,
such as a nursing home or rehabilitation center; this category has increased I.S% for both
conditions over the time period examined (Figure 10D).
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Figure 7
Length of Stay by Payer
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Figure 7 I A. LOS varied for IF A, although Medicaid patients generally stayed the longest
time in hospital (~1 Odays). B. Medicaid patients with PPF also had the longest LOS on
average (~7 days). B-C. Private insurance had the shortest length of stay on average for
PPF and sarcoidosis patients (~5 days for each condition).
IF A, idiopathic fibrosing alveolitis; PPF, postinflammatory pulmonary fibrosis; LOS,
length of stay
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Figure 8

Length of Stay by Gender
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Figure 8 I A-C. Length of stay did not vary greatly when analyzed by gender for each
disease.
IF A, idiopathic fibrosing alveolitis; PPF, postinflammatory pulmonary fibrosis
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Figure 9

Discharges by Gender
56
54

A

B

~ 52

~50

'; 50
1\1
e!' 48

~

e!'

'" 46
~

°4442

~ 30
u

VI

• Fel'Ttale- Djtcharces

IFA
2000

2003

~50

2006

2009

PPF
1997

0

80

60

10

<> Male Oist:ha'IM

0
1997

70

40

25 20

40

C

70
60

~*

••

2000

2003

2006

2009

70
60

.L.-J.-~

•••••••••••••

50

~ 40

VI

1\1

VI

e!'40

'"

.t:

:il 30
25
20

10

1\1

r-r1inlllI--1I-1

e!'

'"u

.t:

30

VI

25 20
•

Sarcoidosis

Female DiKharg.s

10

<> Male Discharges

0

..... Female

All Conditions

-0-Male

0
1997

2000

2003

2006

2009

1997

2000

2003

2006

2009

Figure 9 I A. There were more female discharges from 1997-2002 for IFA, but these
values switched in recent years with males comprising the majority of hospital
discharges. B-C. For PPF and sarcoidosis, there was a ~ 10 to 35%, respectively, greater
percent of female discharges compared to males. Comparatively, IF A discharges by
gender were not as distinct.
IF A, idiopathic fibrosing alveolitis; PPF, postinflarnmatory pulmonary fibrosis
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Figure 10
Discharge Location
A

100

........................

-.

..... .........
~.

~

B

..

30
25
OJ

S ; 20
..,u

-

OJ.&:

..

~ ~ 15
... :1:
.~ OJ

*'o

_IfA

_ _ PPF

5

...... Sarcoidosis

o

o
1997

C

4

~

3.5

S ~

3

al

~

..
~!

"§ S
O~

*'

2000

2003

2006

2009

o

4.5

~

E 10
0
:I:

1997

2000

2003

2006

2009

1997

2000

2003

2006

2009

20

2.S

2

)jj 1.5
.&:

7)

1

«

0.5

c:

o

o
1997

2000

2003

2006

2009

Figure 10 I A. Most patients with PPF (~65%), IFA (50%), and sarcoidosis (~80%)
demonstrated a 'routine discharge' indicating that they returned home with routine care.
However, this number decreased with time. B. Over 15% of patients hospitalized for
PPF and IF A were discharged to home health care. C. The smallest percentage of
discharges were sent to another short-term hospital. D. For PPF and IF A, between 10%
and 15% of patients were discharged to another institution, such as a nursing home or
rehabilitation center; this category has increased 1.8% for both conditions over the time
period examined.
IF A, idiopathic fibrosing alveolitis; PPF, postinfiammatory pulmonary fibrosis
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As expected, a higher percentage of patients with a diagnosis of sarcoidosis were given a
'routine' discharge with fewer sarcoidosis patients discharged from the hospital to home
health care or another facility. In terms of patients admitted to the hospital, a small
percentage (less than
number (reaching

~5%)

~50%)

were admitted from another hospital, while an increasing

were admitted from the emergency department (not shown).

This suggests that there are an increasing number of patients being hospitalized due to
acute complications.

IN-HOSPITAL MORTALITY
As presented in Figure l1A, IF A had the highest in-hospital mortality through the
time period examined with 14.92%, followed by PPF (6.95%), and sarcoidosis showed
the lowest mortality (1.2%). There has been a small decline in in-hospital mortality for
PPF from 9% in 6.95% within the timeframe studied.

In-hospital mortality also

decreased slightly for IFA from 16.89% to 14.92% during the same time interval. Inhospital mortality for sarcoidosis has dropped from 2.3% to 1.2%. In general, in-hospital
mortality is higher for men when compared to women for all three diagnoses (Figures
lIB-D). In terms of in-hospital mortality by age group there did not appear to be a clear
distinction for IF A (Figure 12A). For PPF the 45-64 age group had the lowest mortality
apart from 18-44; however since most patients diagnosed with PPF are older, it is
possible that these were misdiagnoses. The 85+ and 65-84 age groups had similar overall
in-hospital mortalities for PPF except for a two year time span from 2003-2004 in which
the percent mortality was greater for the older age group (Figure 12B). These data
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Figure 11
In-Hospital Mortality by Disease and Gender
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Figure 11 I A. IF A had the highest in-hospital mortality through the time period
examined with 14.92%, followed by PPF (6.95%), and sarcoidosis showed the lowest
mortality (1.2%). B-D. In general, in-hospital mortality is higher for men when compared
to women for all three diagnoses.
IF A, idiopathic fibrosing alveolitis; PPF, postinflammatory pulmonary fibrosis
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Figure 12

In-Hospital Mortality by Age Group
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Figure 12 I A. In tenns of in-hospital mortality by age group there did not appear
to be a clear distinction for IF A. B._For PPF the 45-64 age group had the lowest
mortality apart from 18-44; however since most patients diagnosed with PPF are
older, it is possible that these were misdiagnoses_ The 85+ and 65-84 age groups
had similar overall in-hospital mortalities for PPF except for a two year time span
from 2003-2004 in which the percent mortality was greater for the older age
group.
IF A, idiopathic fibrosing alveolitis; PPF, postinflammatory pulmonary fibrosis
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suggest that after a certain age

(~65

and older) the age of the patient does not playas

important a role in affecting survival.

HOSPITALIZA nON CHARGES
Hospitalization charges have increased for all conditions since 1993 reaching
~$30,000

on average (Figure 13A). Similarly, hospitalization charges also increased for

IF A, PPF and sarcoidosis. However, while hospitalization charges for PPF ($15,000 to
over $40,000, 298% increase) and sarcoidosis ($12,563 to over $37,000, 349% increase)
have increased at a similar rate, hospitalization charges for IF A have increased
dramatically in recent years. IF A patients are consistently most costly, especially in the
last two years of the analysis when the in-hospital charges for IF A experienced a sharp
increase reaching $81,000. Differences in hospitalization charges were noted when data
were analyzed by region. For sarcoidosis and PPF, hospitalization charges were highest
in the West and similar trends were noted for IF A although data for the latter diagnosis
are limited (Figures 13B-D). We also analyzed mean charges by payer (Figure 14A-C).
For IF A, private insurance charges were consistently one of the highest reaching over
$100,000 in the past two years. For PPF, Medicaid patients were charged the most on
average from 1997-2009 and these charges were paralleled and surpassed, in the past
year, by private insurance charges (which reached almost $60,000 in 2009). Charges for
uninsured patients on average were the least during the twelve year timespan.
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Figure 13

Mean Charges by Condition and Region
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Figure 13 I A. Hospitalization charges for all conditions, as well as IF A, PPF, and
sarcoidosis have increased. Hospitalization charges for IF A have increased dramatically
in the past two years. B-D. For sarcoidosis and PPF, hospitalization charges were highest
in the West and similar trends were noted for IF A although data for the latter diagnosis
are limited.
IF A, idiopathic fibrosing alveolitis; PPF, postinflammatory pulmonary fibrosis
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Figure 14
Mean Charges by Payer
A
150,000

E

...... Medicare

III

:1:,100,000

...

'"

~Medicald
~Private

Insurance
___ Uninsured

.4:

U

,

c:

gj 50,000

:E

B

°

1997

2001

2005

2009

80,000
...... Medicare

PPF

~Medicaid

E 60,000
III

~Private

Insurance
___ Uninsured

~

140,000
u
c:

~'" 20,000

c

°
60,000

1997

2000

~Medicaid

~

-o-Private Insurance
___ Uninsured

40,000

2006

2009

...... Med'care

_ 50,000
~

2003

~

1 30,000
u

:; 20,000

w

:E 10,000

° 1997

Sarcoidosis
2000

2003

2006

2009

Figure 14 I A. For IF A, private insurance charges were consistently one of the highest
reaching over $100,000 in the past two years. B. For PPF, Medicaid patients were
charged the most on average from 1997-2009 and these charges were paralleled and
surpassed, in the past year, by private insurance charges (which reached almost $60,000
in 2009). Charges for uninsured patients on average were the least during the twelve year
timespan. C. For sarcoidosis there is no clear separation of charges by payer, except for
uninsured patients for the past several years were approximately $10,000 cheaper than
other payers.
IF A, idiopathic fibrosing alveolitis; PPF, postinflammatory pulmonary fibrosis
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For sarcoidosis there is no clear separation of charges by payer, except for uninsured
patients for the past several years were approximately $10,000 cheaper than other payers.
For IFA (Figure 15A) charges for males have been ~$4,000 higher every year and the gap
has increased further in the past few years

(~$90,000

for males vs.

~$60,000

for females

in 2009). Mean charges by gender were very similar for males and females for PPF and
sarcoidosis (Figure 15B-C) and it is not until the past few years that a difference was seen
(with males having more mean charges for both conditions).

The effect of income on

in-hospital mortality was analyzed (Figure 16A-B) for IF A and PPF.

No distinct

difference was seen for IF A and PPF suggesting that the mortality rate is not affected by
the patient's income level.
Considering that there are significant differences in age of diagnosis for IF AlPPF
(more common in elderly subjects) and sarcoidosis (more common in younger subjects)
(Figure 17B-D), we analyzed the data for each condition based on the percent discharges
based on age group and compared this to discharges for all conditions (Figure 17A). IF A
and PPF had similar age distribution with the greatest percent of patients being part of the
65-84 age range (Figure 17B-C). For sarcoidosis, there was a steady increase in the
percent of 45-64 year old patients, with a corresponding decrease seen in the percent of
18-44 year old patients (Figure 17D). The decrease in percent discharges of 18-44 year
old patients might imply that these patients are living longer and, as such, more are
surviving into older age. The decreasing mortality rate for patients with sarcoidosis also
supports this idea. However the increasing average age of the American population may
also be affecting these data.
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Figure 15 I A. Charges for males have been ~$4,000 higher every year and the gap has
increased further in the past few years (~$90,000 for males vs. ~$60,000 for females in
2009). B-C. Mean charges by gender were very similar for males and females for PPF
and sarcoidosis and it is not until the past few years that a difference was seen (with
males having more mean charges for both conditions).
IF A, idiopathic fibrosing alveolitis; PPF, postinfiammatory pulmonary fibrosis
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Figure 16 I A-B. The effect of income on in-hospital mortality was analyzed for IF A and
PPF. No distinct difference was seen for IFA and PPF suggesting that the mortality rate
is not affected by the patient's income level.
IF A, idiopathic fibrosing alveolitis; PPF, postinflammatory pulmonary fibrosis
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Figure 17
Discharges by Age Group
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Figure 17 I A. Discharges for all conditions saw ~5% increase in discharges for patients
in the 45-64 age range. B-C. IF A and PPF had similar age distribution with the greatest
percent of patients being part of the 65-84 age range. D. For sarcoidosis, there was a
steady increase in the percent of 45-64 year old patients, with a corresponding decrease
seen in the percent of 18-44 year old patients.
IF A, idiopathic fibrosing alveolitis; PPF, postinflammatory pulmonary fibrosis
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We further analyzed these trends by detennining the number of discharges, based on
condition, per million people by state for 2000 and 2010. We arranged the states in order
of youngest to oldest states (states with a smaller % of the population older than 45 years
of age were considered younger).

It was hypothesized that as the average state age

increased, that the number of discharges/million people would increase for IF A and PPF
since these diseases are predominantly seen in elderly. However, for each entity, there
was no distinct correlation between 'older' states and more discharges/million people
(Figure 18A-C).

DISCUSSION

IPF is a progressive fibrotic lung disorder that affects close to 200,000 Americans
and many more worldwide. Its high mortality rate, the lack of effective therapies, and
recent studies showing that IPF incidence is increasing, have prompted much attention.
However, little is known about IPF hospitalization rates and in-hospital mortality. It was
our intention to evaluate trends for hospitalization, length of stay, in-hospital mortality,
and charges for subjects carrying a diagnosis of IPF over the last two decades. However,
analyzing these parameters remains a difficult task considering the limitations of the
databases available and the changes that have occurred regarding the diagnosis of IPF
which limit the accuracy of the classification of this disease in hospital documents for this
time period. Considering the above, we opted for evaluating hospitalizations related to
the diagnosis of IF A, which is most compatible with the diagnosis of IPF, and PPF,
which is likely to include all fonns of pulmonary fibrosis independent of the cause.
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Figure 18
Discharges/Million People by Increasing Average State Age

A

15

01

a.
o

:. 10
c

~

:i
.....

5

III

01

~

IFA - 2010

0

.t::.

~

o
B
01

100

a.
0

80

C

60

01
Q.

~ 40

:i
.....

..
01

20

C'O

0

III

PPF - 2010

QI)

.t::.
U

III

0

C
01

60

Sarcoidosis - 2010

a.
50
0
01
Q.

c

40

~

30

III

20

:i
.....
...
01

QI)

C'O

.t::.
u

III

0

10

0

Note: States are arranged from left to right by increasing percent state population 65
years of age and older.
Figure 18 I A-C. No distinct correlation was seen between states with older populations
and the number of discharges/million people.
IF A, idiopathic fibrosing alveolitis; PPF, postinflammatory pulmonary fibrosis
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Although it is likely that not all diagnoses of IF A were accurate, the database provides a
window into the burden of pulmonary fibrosis in this country as it relates to
hospitalization.
Analysis of these data revealed that, during the 15 year period considered by the
HCUPnet Database (1993-2008), there was an increase in hospitalizations related to PPF
when compared to IF A and sarcoidosis; the latter remaining relatively stable in
comparison. Most patients in our cohort were hospitalized with other primary diagnoses
(with PPF, IF A and sarcoidosis listed as secondary diagnoses) suggesting that subjects
with these conditions are frequently hospitalized due to co-morbidities or the need for
procedures. It is likely that some patients with IPF hospitalized with a diagnosis of
pneumonia and congestive heart failure suffered instead from an acute exacerbation of
IPF [20], but this could not be ascertained.

Other co-morbidities included essential

hypertension, hyperlipidemia, and diabetes; conditions typically seen in the elderly. The
presence of these conditions is not surprising considering that IPF is more common with
aging [3]. Secondary diagnoses related to drug toxicity were also relatively common in
the IF A group, but no data were available for the other two groups.

Until recently,

patients with pulmonary fibrosis were frequently treated with immunosuppressive agents.
The use of immunosuppressants may explain why in our cohort, up to 16% of patients
hospitalized for IF A in 2008 suffered from adverse effects of medical drugs, which was
associated with 18.63% in-hospital mortality.
Regarding length of stay, we found a 1-3 day higher length of stay for PPF, IFA
and sarcoidosis when compared to all conditions, with IF A having the highest length of
stay (7.2 days in 2008).

However, over the period of the analysis, length of stay
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decreased for all three conditions. This is likely due to pressures imposed on physicians
for decreasing length of stay and to the increasing recognition that many of the comorbidities related to these disorders can be treated in the ambulatory setting. No major
differences were noted when gender was analyzed and when U.S. regions were
compared.
We then determined where the patients were sent after their hospitalization. We
noted that by 2008, over 15% of patients hospitalized for PPF and IF A were discharged
to home health care, which has been increasing steadily over the years, and a smaller
percentage was discharged to another short-term hospital. For PPF and IF A, between
10% and 15% of patients were discharged to another institution, such as a nursing home
or rehabilitation center. This percentage has not changed much since 1993, but certainly
adds to the financial burden of families caring for loved ones with these disorders.
In-hospital mortality was highest in the IFA group (14.92%), while PPF had
6.95% in-hospital mortality. As expected, a much lower mortality rate was noted for
sarcoidosis (1.2%).

The in-hospital mortality for all groups has declined in the past

years. Of note, in-hospital mortality for men was much higher than for women. This
gender-based difference is quite intriguing, and some studies have reported female sex as
having a protective effect and worse survival in males, but the factors responsible for it
remain unclear [64, 65].
Finally, we examined hospitalization charges which, as expected, have increased
for all conditions since 1993. Hospitalization charges have also increased for IF A, PPF
and sarcoidosis. However, while hospitalization charges for PPF and sarcoidosis have
increased steadily, hospitalization charges for IF A increased dramatically in recent years.
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IF A patients are consistently most costly, especially in the last two years analyzed when
the in-hospital charges for IF A experienced a sharp increase reaching $81,000. The
highest charges were noted for the West region of the U.S. It is unclear how these
findings are influenced by hospitalizations related to lung transplantation.
This study has a number of limitations, the most important of which relates to the
accuracy of diagnosis. Considering the difficulties inherent in the diagnosis of IPF and
related disorders, and the changes made in the diagnosis and classification of idiopathic
interstitial pneumonias over the past two decades [3, 60], it is likely that there were
misdiagnoses present in the database. Also, some patients may have been counted more
than once since there were no unique patient identifiers [66]. However, many of the
findings presented were consistent with expectations considering what we know about
these disorders. For example, mortality was higher in patients with IF A and PPF when
compared to sarcoidosis, while the sarcoidosis affected more females and younger
individuals. The data suggest that hospitalization rates for pulmonary fibrotic disorders
have increased in this country and that these disorders are associated with significant
mortality and charges.

When evaluating hospitalizations where the primary diagnosis

was IFA or PPF, we estimate that these conditions accounted for 33,513 hospitalizations
and 205,293.6 hospitalizations days in 2008. About 2,609 of these patients died while in
the hospital for 7.8% in-hospital mortality.

Importantly, the charges of these

hospitalizations were estimated to be almost $1.5 billion dollars in 2008 (Table 4).
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Table 4

Hospitalization charges, LOS*, and mortality for patients hospitalized for IF A *, PPF*,
and sarcoidosis (2008)**
Parameter

IFA

PPF

Sarcoidosis

Hospitalizations

3,513

28,732

7,588

LOS (days)

9.3

6

6.2

Mortality (%)

14.92

6.95

1.2

Charges ($)

81,000

40,000

37,000

Overall charges
(Millions of $)

285

1,149

281

*** Avg. Charges/

56,797

229,397

56,039

Hospital ($)
*IFA, idiopathic fibrosing alveolitis; PPF, postinfiammatory pulmonary fibrosis; LOS, length of stay

**[11], ***[67]
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In conclusion, despite limitations in diagnosis accuracy, our data suggest that
hospitalization rates for pulmonary fibrosis increased in the past two decades. Despite
decreases in length of stay and in-hospital mortality, charges have continued to increase
reaching close to 1.5 billion dollars in 2008.
admitted because of co-morbidities.

The majority of these patients were

Considering that we have limited options when

treating fibrosis, the early identification and efficient treatment of co-morbidities might
decrease hospitalizations, in-hospital mortality, and overall hospitalization charges for
patients with pulmonary fibrosis.
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IDENTIFYING TARGETS FOR INTERVENTION

Understanding the impact of IPF to the healthcare system and patients is an
integral step in taking measures to address the burden of this disease. However, any
potential cure or drug therapy for IPF is likely to stem directly from laboratory research.
In order to address the need for further understanding of disease pathogenesis, efforts
were placed to understand the role of the extracellular cysteine/cystine redox potential
(Eh Cys/CySS).
Oxidant stress has been implicated in the pathogenesis of IPF. In fact, a clinical
trial is being conducted by the NIH-sponsored Idiopathic Pulmonary Fibrosis Clinical
Research Network to test the potential role of an anti-oxidant (N-acetylcysteine) in the
treatment of this condition; the results of this trial will not be available until late 2013
[29]. One form of oxidant stress is through oxidation of the Eh Cys/CySS, which reflects
the predominant low-molecular-weight thiolldisulfide pool in the plasma [68].

Eh

Cys/CySS has been found to be approximately -80 mV in normal individuals. However,
the Eh Cys/CySS becomes more oxidized during aging and disease (e.g., cardiovascular
and pulmonary diseases) as well as the exposure to chemotherapy and agents like tobacco
smoke and alcohol [69].
Roman and colleagues have reported that lung fibroblasts exposed to oxidized Eh
Cys/CySS increase their proliferation as well as their expression of markers for
myofibroblast transdifferentiation (i.e., a-smooth muscle actin, fibronectin) [70].
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Furthermore, it appears that these changes are mediated by their expression of
the pro-fibrotic growth factor Transforming Growth

Factor~.

More recently, the Roman

group has obtained plasma samples from IPF patients recruited to the IPF trial described
above and found that most subjects with IPF show oxidation of their Eh Cys/CySS
(unpublished results). It is for this reason that the Roman laboratory is exploring how
this form of oxidant stress can affect fibroblast functions.
Considering the connection between an oxidized Eh Cys/CySS and lung
fibroblasts, we turned our attention to oxidant stress and its relationship to lung fibrosis
and lung cancer. Others have reported that IPF subjects have a higher incidence of lung
cancer compared to controls.

Based on the information presented before, we

hypothesized that oxidation of the Eh Cys/CySS in IPF subjects may stimulate lung
fibroblasts to secrete agents that could influence the proliferation of cancer cells. This
hypothesis was tested in vitro as described below.

METHODS

CELL CDL TDRE
We used primary lung fibroblasts (PLF) harvested from mouse lungs as described
previously [71].

Primary murine fibroblasts were obtained from C57BLl6 mice. Lung

tissue sections were isolated, washed twice with sterile PBS, resuspended in DMEM
supplemented with 10% FBS and 1% antibiotic-antimycotic solution (100 D/ml penicillin
G sodium, 100 D/ml streptomycin, and 0.25

~g/ml

amphotericin B), and then transferred

to a tissue culture dish and incubated in a humidified 5% CO2 incubator at 37°C for 1-3
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weeks to allow for the fibroblasts to migrate out of the tissue sections. Cells used for
experiments were between passage 3 and 8.
CREATION OF CONDITIONED MEDIA
To create the media used to treat the cancer cell lines tested (Lewis Lung
Carcinoma, H1792 and H460), PLFs were plated (lxl0 6 cells/well in a 6 well plate) and
then grown in serum free media for 24 hours. This media was aspirated and the wells
were gently washed with PBS. Redox media (of varying mV potentials) was then added
to each of the wells of the plate (described below). Values of -46mV and -80mV were
chosen for comparison between an oxidized and healthy state, respectively.

After

incubating for 24 or 72 hours in either -46 or -80mV redox media, the supernatant was
removed and saved. At this point, the supernatant is referred to as 'conditioned media.'
The conditioned media from the PLFs was then used for experiments with Lewis
Lung Carcinoma (LLC) cells, which are lung cancer cells harvested from mice, and later,
with two different human lung cancer cell lines (H460 and H1792).

The respective

cancer cell lines were plated in 96 well plates, grown in complete serum-free/low-protein
media, and then treated with conditioned media for 24, 48, and 72 hours. After each of
these time points the cells were tested for differences in proliferation using an ATP
proliferation assay and apoptosis using a caspase 3/7 assay.

ATP PROLIFERATION AND CASPASE APOPTOSIS ASSAYS
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The A TP assay was performed using the protocol defined by Promega for their
CellTiter-Glo® Luminescent Cell Viability Assay product. Briefly, the assay reagent and
cell culture plate were allowed to equilibrate to room temperature.

One hundred

microliters of reagent were added per well in the 96-well plate and then the plate was
mixed gently for 2 minutes to induce lysis. The plate was then allowed to equilibrate to
room temperature for 10 minutes before luminescence (produced by the luciferase
reaction) was recorded using a luminometer.

The assay reagent generates a signal

proportional to the amount of ATP present.
The Caspase-317 assay was performed according to the protocol defined by
Promega for their Caspase-Glo® 317 Assay as

described on their website

(www.promega.com).Briefly. the caspase reagent and cell culture plate were brought to
room temperature, 100 microliters of the reagent was added to each well of a 96 well
plate. The plate was allowed to gently mix for 30 minutes before the luminescence of
each sample was detected using a luminometer.

ESTABLISHING EXTRACELLULAR REDOX MEDIA
The Eh Cys/CySS was manipulated by varying concentrations of cysteine and
cystine added to cyst(e)ine-free DMEM, which contains 4 mM glutamine, 10 U/ml
penicillin, and 10 Ilg/ml streptomycin.
The first step in preparation of Eh Cys/CySS involved creating 10 mM stock
solutions of cysteine and cystine, respectively. The stock solutions were adjusted to a pH
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of 7.4 and then sterile filtered. The stock solutions were then added in a precise ratio to
cystine-free media to create -46 or -80mV redox media.
CALCULAnON OF EH

Eh = Eo + RT/2Fln ([cystine]/[cysteine])2
Eh represents the electromotive force (given in V or mV) relative to a standard
hydrogen electrode, R is the gas constant, T is the absolute temperature, F is Faraday's
constant, and Eo is the standard electrode potential (-0.250 V at pH 7.4) for the
cysteine/cystine redox couple.
Prior to placing the redox media on the cell line to be tested, the cells were
starved in complete serum free media for 24 hours. The cells were then washed gently in
PBS, the PBS was aspirated and then the cells were cultured in the -46 or -80mV redox
media for 24 hours.

RESULTS

First, we tested the effects of normal (-80 mM) and oxidized (-46 mM) Eh
Cys/CySS media on the proliferation of LLCs. As presented in Figure 19, we found no
differences in cell proliferation when the cells were treated directly with -46 or -80mV
redox media at 24, 48 and 72 hours. We, therefore, turned our attention to the effects of
fibroblast conditioned media on the proliferation of LLCs. We tested the proliferation of
LLCs cultured with the supernatant derived from lung fibroblasts exposed to normal and
oxidized Eh Cys/CySS.

Specifically, we cultured the fibroblasts in the normal and

oxidized Eh Cys/CySS media for 24 or 72 hours. The proliferation of LLCs was then
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Figure 19
Lewis Lung Carcinoma (LLC) Cell Viability Assay - Response to Redox Media
24 Hour Cell Viability Assay - llCs
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Figure 19 I A-C. No difference was seen in cell proliferation when LLCs were treated
directly with -46 or -80mV redox media. LLCs cultured in the presence of conditioned
media (CM -46 or -80mV) showed a significant decrease in proliferation in the CM
-46mV compared to the CM -80mV control group. This effect was seen in response to
conditioned media that was left on primary lung fibroblasts for 72 and 24 hours.
Note: CM = Conditioned Media (supernatant from -46mV or -80mV treated primary lung
fibroblast cells). N=5 for each treatment group. Error bars are standard deviations.
Statistical significance was calculated using a ttest, where p<O.05 was considered
statistically significant.
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evaluated for 24, 48, and 72 h.

As seen in Figure 19, LLC cells cultured with the

supernatant of lung fibroblasts exposed to oxidized Eh Cys/CySS (-46mV) showed
decreased proliferation compared to LLCs cultured in media obtained from fibroblasts
exposed to a more reduced Eh Cys/CySS (-80m V).

This relationship was more

prominent when the fibroblasts were maintained in culture for 72 hours, rather than only
24.
We then tested the effects of these manipulations on human lung cancer cells
H460 and H1792. Again, we noted that direct exposure of these cells to normal and
oxidized Eh Cys/CySS had no effect.

However, tumor cells exposed to supernatant

obtained from fibroblasts exposed to oxidized Eh Cys/CySS (indirect exposure) showed
decreased proliferation when compared to LLC cells exposed to media from fibroblasts
exposed to normal Eh Cys/CySS (Figures 20-21).
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Figure 20
H460 and H1792 (Human Cancer Cell Lines)
Cell Viability Assay - Response to Redox Media
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Figure 20 I A-D. No difference was seen in cell proliferation when H460 or H1792 cells
were treated directly with -46 or -80mV redox media. Both cell lines cultured in the
presence of conditioned media (CM -46 or -80m V) showed a significant decrease in
proliferation in the CM -46mV compared to the CM -80mV control group. However,
H460 cells only showed a statistically significant decrease in proliferation at 48 hours.
Note: CM = Conditioned Media (supernatant from -46mV or -80mV treated primary lung
fibroblast cells). N=5 for each treatment group. Error bars are standard deviations.
Statistical significance was calculated using a tiest, where p<0.05 was considered
statistically significant.
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Figure 21

H460 and H1792 Human Cancer Cells - Response to Redox Media (Continued)
72 Hour Cell Viability Assay - H460
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Figure 21 I A-B. No difference was seen in cell proliferation when H460 or H1792 cells
were treated directly with -46 or -80mV redox media at 72 hours. Both cell lines cultured
in the presence of conditioned media (CM -46 or -80mV) showed a significant decrease
in proliferation in the CM -46mV compared to the CM -80mV control group.
Note: CM = Conditioned Media (supernatant from -46mV or -80mV treated primary lung
fibroblast cells). N=5 for each treatment group. Error bars are standard deviations.
Statistical significance was calculated using a ttest, where p<O.05 was considered
statistically significant.
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The caspase assay measures the amount of cleaved caspase enzymes, specifically
caspase-3 and caspase-7, which are the active forms present during programmed cellular
death. As depicted in Figure 22, we found that apoptosis was not different in tumor cells
exposed directly to normal versus oxidized Eh Cys/CySS. However, their proliferation
was decreased when exposed to the conditioned media.

Although proliferation was

decreased, indirect exposure to the redox media (using conditioned media) did not
differentially affect apoptosis.
Together, our studies suggest that oxidation of Eh Cys/CySS in subjects with IPF
may stimulate lung fibroblasts to produce agents that may indirectly influence the
proliferation of lung cancer cells. Specifically, the secreted agents reduce lung cancer
cell proliferation. Lung fibroblasts appear to either secrete agents, or metabolize positive
factors, that affect lung cancer cell proliferation. The difference in proliferation did not
appear to be affected by oxidation of the Eh Cys/CySS. Thus, we conclude that an
oxidized Eh Cys/CySS stimulates lung fibroblasts to produce agents, or metabolize
factors, that decrease tumor cell proliferation through effects on cell cycle rather than by
inducing apoptosis.

Future efforts focusing on the identification of the mechanisms

responsible for the effects observed could prove beneficial in the field of IPF, since this
work may unveil potential targets for intervention.
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Figure 22
Caspase-317 Assay
72 Hour Caspase Assay - LLCs
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Figure 22 I Apoptosis was not different in LLCs exposed directly to nonnal versus
oxidized Eh Cys/CySS. However, their proliferation was decreased when exposed to the
conditioned media. Although proliferation was decreased, indirect exposure to the redox
media (using conditioned media) did not differentially affect apoptosis.
Note: CM = Conditioned Media (supernatant from -46mV or -80mV treated primary lung
fibroblast cells). LLCs = Lewis Lung Carcinoma Cells. N=4 for each treatment group.
Error bars are standard deviations. Statistical significance was calculated using a tiest,
where p<O.05 was considered statistically significant.
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FUTURE WORK
As this document suggests, efforts focused on elucidating disease pathogenesis
and treatment are still greatly needed for tackling IPF as clinical trials have yet to reveal a
drug to serve as a magic bullet for targeting this condition. There are several clinical
trials testing new drugs/drug combination therapies, however, these trials are time
sensitive and often take several years to complete and analyze. The value of these trials
is great, but efforts should also be focused on determining potential genetic links to IPF.
Studies of familial IPF have been essential in helping piece together a potential
mechanism of disease pathogenesis, yet there is still much work that can be done in this
area. Genetic studies may prove invaluable as a source for identifying genetic links to
disease. Identifying genes implicated in IPF pathogenesis could provide targets for future
drug therapies.
The most common animal model of IPF is the bleomycin model used in rodents.
However, drug therapies shown to be effective in the bleomycin model have not been
shown to provide the same clinically meaningful benefits in human studies. Alternative
animal models, that better recapitulate the pattern of IPF, are needed. It is interesting to
note that other species develop lung fibrosis. Lung fibrosis has been demonstrated in
domesticated animals such as cats, dogs, horses and donkey as well as in birds. These
animals share our environment and may represent models of naturally-occurring disease.
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If so, evaluating for clues in these models may accelerate discovery in this field, by
providing a more realistic model of lung fibrosis.
Considering the ever changing healthcare landscape, it is important that we
continue to evaluate the impact of IPF on healthcare costs since new information in this
area may lead to alterations in the way healthcare is delivered in order to provide the best
care to patients while relieving healthcare organizations and families from unnecessary
financial burden. Regarding the HCUP database, we propose that further efforts should
be directed towards determining a connection between states with lower mortality rates
and differences in treatment/standards of care for IPF patients in that region. It needs to
be determined if there are specific states with consistently lower percentages of hospital
mortality.

In addition, any association the lowered mortality rates may have with

lowerlhigher hospital charges, and, most importantly, what is the cause of the lowered
mortality.

Factors such as local lung disease clinics (which may allow for earlier

detection/treatment of IPF and any comorbidities), different drug combinations, and the
quality of/access to hospitals are a few of the possibilities that should be considered.
It is clear that significant advances in the management of IPF will come only

through rigorous exploration of the basic mechanisms of action responsible for the
development and progression of IPF.

Also, further understanding of the impact this

disease has on the development of comorbidities such as lung cancer is important. The
conditioned media model presented here may be used to identify fibroblast-derived
products that affect lung cancer cell proliferation.
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CLOSING SUMMARY

IPF is a chronic progressive fibrotic lung disease. This disease primarily affects
the elderly and has a median survival of approximately 3 years. There are no drugs that
have been shown to halt or reverse the progression of this disease and lung
transplantation is the only approved surgical treatment to extend survival for these
patients. Patients with IPF are burdened with declining respiratory function, hospital
charges that far exceed that of most conditions, and are often afflicted with comorbidities
that further the difficulty of living with the disease.
Although the current situation for these patients is dire, there is promise in future
efforts to treat IPF. Emerging clinical trials, increased awareness and research efforts,
and a greater understanding of disease pathogenesis all point towards improved
survivability, quality of life, and treatment options for IPF patients in the future.
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